RE:Performance and ComplaintsBigkahuna57 wrote: JMO: If you take the side of the argument that management has fallen short - without considering the challenges of finance and lab resources, then you also have to consider that there's a distinct possibility that there have been offers. Those offers mostlikely have been made with an NDA, so we won't hear about it. Why would the possibly suitor expose their interest to other oncology competitors? You wouldn't, I wouldn't and they shouldn't. Also, how much of the company would/did the possible suitor require in value for $XM or $XXM dollars? How do you value the company and the known indications? I think offer(s) have been made, and they were predatory and onerous. Without "selling" a percentage of the company, what else could be done except work the science down the course of the trial and continue proving that it works through the data. So long as the company can maintain the patient treatment and data - the rest get's worked out on its own time line. There's no other choice. Except to complain.
GLTA
Regards, BK
I apologize in advance if this has been discussed, but how long is our IP protected here?
Wouldnt it be a better strategy to wait out movement in the FDA's designation or ongoing funding faltering before trying to make a move?